Balchem announced that on December 5, 2022, its Board of Directors declared a dividend on its shares of common stock equal to $0.71 per share on the Company's issued and outstanding Common Stock, to be payable on January 20, 2023 to stockholders of record at the close of business on December 27, 2022. This dividend represents an 10.9% increase over last year's annual dividend.
Ted Harris, Balchem's Chairman, President, and CEO, said, "Balchem has a long-standing commitment to an annual dividend and we are pleased to announce the continuation of that commitment. This dividend represents the fourteenth consecutive increase in our annual dividend, reflecting both the consistently outstanding financial performance the company has delivered and the Board's continued confidence in our long-term strategies."
Balchem Corporation published this content on 06 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 December 2022 14:41:05 UTC.
Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. The Company's segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. Through Specialty Products, it re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.
BALCHEM CORPORATION 
